New scan could spot hidden prostate cancer spread

NCT ID NCT07615101

Not yet recruiting Diagnosis Sponsor: Norroy Bioscience Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing a new radioactive imaging agent called 68Ga-NYM032, given as an injection before a PET/CT scan, in 365 men newly diagnosed with prostate cancer. The goal is to see if this scan can accurately detect whether the cancer has spread to pelvic lymph nodes, compared to standard tissue analysis after surgery. If it works, it could help doctors decide on the best treatment without needing invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-NYM032 (a radioactive imaging agent injected intravenously for PET/CT scans)
What this could lead to: If successful, this could provide a more accurate, non-invasive way to detect whether prostate cancer has spread to nearby lymph nodes, helping guide treatment decisions.
What could go wrong: This is still an experimental imaging agent. It may not prove more accurate than current methods, and results from this single-arm study may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (DIAGNOSIS)

More trials for these conditions

Other studies related to the condition(s) this trial covers.